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We respond to the comments made in the BBC commissioned
article by Heneghan and colleagues and the Panorama
programme by Deborah Cohen about pre-implantation genetic
screening (PGS), which was among the three “add on”
treatments highlighted in the programme and the 41 listed in
the article.1 2 Currently an extensive evidence base supports the
efficacy of PGS: more than 20 retrospective studies and four
randomised controlled trials suggest that, if performed to a high
standard, PGS can, and does, improve IVF success for some
patient groups.3-7 We accept, however, that all studies are open
to criticism and thus support further investigations, randomised
and retrospective. However, the programme, in our view
misleadingly, gives the impression of viewing PGS as
unsupported by published evidence. We also question the
wisdom of highlighting the opinion of only one laboratory,
known opponents of PGS, without providing balance by
presenting the evidence base in favour of PGS.
We are strong advocates of evidence based medicine and agree
that medical practice should be supported by “well designed
and conducted studies.” We emphasise, however, that the quality
of study design is comparatively easy to assess by reading an
article: whether the study has been well conducted is more
difficult to judge. The study by Mastenbroek et al (the only one
cited in the programme) is a clear example8: mining the evidence
indicates that the authors’ specific practice of cleavage stage
embryo biopsy, not screening for chromosome abnormalities
in itself, led to reduced IVF success/pregnancy rates. In any
case, PGS has now moved on to trophectoderm biopsy and
whole karyotype screening (both improved procedures) and
higher quality embryological practice.
We thus offer the hand of collaboration to the Oxford group in
the hope of working together to consider the evidence base that
supports IVF innovations in general (and PGS in particular) in
its unique setting. In a discipline in which the outcome measure
is the likelihood of achieving a healthy live birth, countless
individual components can have a profound effect on the success
of IVF. To assess each individually in randomised controlled
trials would be prohibitive and far too late for many: indeed
d.k.griffin@kent.ac.uk
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2017;356:j752 doi: 10.1136/bmj.j752 (Published 2017 February 14) Page 1 of 2
Letters
LETTERS
patients may be denied the opportunity of the highest quality
treatment until the trial was published (and no doubt criticised
further). The hitherto unpublished ESTEEM trial is a good
example, to date criticised for its recruitment strategy, mixed
skill variance, and now out of date technology.9
Together we can consider the comparative value of single centre
and retrospective studies and the possible pitfalls surrounding
relying on randomised controlled trials alone. We should also
consider the implications of not implementing PGS—for
example, the harm that could be caused to patients who have
an adverse outcome assuming that they could, and would, have
chosen to avoid it had PGS been offered.
We all want every patient receiving IVF to be given the highest
possible chances of success. With an open minded, pragmatic
approach to evidence based medicine, we can increase success
rates further.
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Full response at: http://www.bmj.com/content/355/bmj.i6295/rr-1.
1 Heneghan C, Spencer EA, Bobrovitz N, et al. Lack of evidence for interventions offered
in UK fertility centres. BMJ 2016;356:i6295. doi:10.1136/bmj.i6295 pmid:27890864.
2 Panorama. Inside Britain’s fertility business. BBC. Last on BBC2, 2 Dec 2016. Available
till December 2017 at http://www.bbc.co.uk/programmes/b084ngkd.
3 Lee E, Illingworth P, Wilton L, Chambers GM. The clinical effectiveness of preimplantation
genetic diagnosis for aneuploidy in all 24 chromosomes (PGD-A): systematic review.
Hum Reprod 2015;356:473-83. doi:10.1093/humrep/deu303 pmid:25432917.
4 Dahdouh EM, Balayla J, García-Velasco JA. Comprehensive chromosome screening
improves embryo selection: a meta-analysis. Fertil Steril 2015;356:1503-12. doi:10.1016/
j.fertnstert.2015.08.038 pmid:26385405.
5 Chen M, Wei S, Hu J, Quan S. Can comprehensive chromosome screening technology
improve IVF/ICSI outcomes? A meta-analysis. PLoS One 2015;356:e0140779. doi:10.
1371/journal.pone.0140779. pmid:26470028.
6 Chang J, Boulet SL, Jeng G, Flowers L, Kissin DM. Outcomes of in vitro fertilization with
preimplantation genetic diagnosis: an analysis of the United States Assisted Reproductive
Technology Surveillance Data, 2011-2012. Fertil Steril 2016;356:394-400. doi:10.1016/j.
fertnstert.2015.10.018 pmid:26551441.
7 Virtual Academy of Genetics. A statement on the use of preimplantation genetic screening
(PGS) of chromosomes for IVF patients. 2015. http://www.ivf-worldwide.com/cogen/
general/cogen-statement.html
8 Mastenbroek S, Twisk M, van Echten-Arends J, et al. In vitro fertilization with
preimplantation genetic screening. N Engl J Med 2007;356:9-17. doi:10.1056/
NEJMoa067744 pmid:17611204.
9 European Society of Human Reproduction and Embryology. About ESTEEM. https://www.
eshre.eu/Data-collection-and-research/ESTEEM/About-ESTEEM.aspx
Published by the BMJ Publishing Group Limited. For permission to use (where not already
granted under a licence) please go to http://group.bmj.com/group/rights-licensing/
permissions
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2017;356:j752 doi: 10.1136/bmj.j752 (Published 2017 February 14) Page 2 of 2
LETTERS
